Stan B. Kaye
Impact in
- Reproductive Medicine top 0.1%
- Ovarian cancer diagnosis and treatment
- Oncology top 0.1%
- PARP inhibition in cancer therapy
- Cancer Treatment and Pharmacology
Papers in
- Oncology 87
- Cancer Treatment and Pharmacology 30
- PARP inhibition in cancer therapy 26
- Colorectal Cancer Treatments and Studies 14
-
- Ovarian cancer diagnosis and treatment 71
- Co-authors
- Johann S. de Bono (54 shared papers)Roshan Agarwal (4 shared papers)Timothy A. Yap (19 shared papers)Alan Ashworth (6 shared papers)Andrew Tutt (5 shared papers)James Carmichael (4 shared papers)David S.P. Tan (6 shared papers)Jan H.M. Schellens (8 shared papers)
- Journals
- Journal of Clinical Oncology (34 papers)British Journal of Cancer (26 papers)European Journal of Cancer (24 papers)Annals of Oncology (17 papers)Clinical Cancer Research (11 papers)
- Partner nations
- United KingdomUnited StatesNetherlands
In The Last Decade
Stan B. Kaye
213 papers receiving 18.9k citations
Stan B. Kaye's Hit Papers
Peers
Comparison fields: 5 of 153
- Reproductive Medicine 2.7k
- Oncology 8.0k
- Cancer Research 2.8k
- Pulmonary and Respiratory Medicine 3.4k
- Molecular Biology 7.4k
Countries citing papers authored by Stan B. Kaye
This map shows the geographic impact of Stan B. Kaye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stan B. Kaye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stan B. Kaye more than expected).
Fields of papers citing papers by Stan B. Kaye
This network shows the impact of papers produced by Stan B. Kaye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stan B. Kaye. The network helps show where Stan B. Kaye may publish in the future.
Co-authors
The 25 scholars most cited alongside Stan B. Kaye, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 217 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers Hit paper breakdown → | 2009 | 2716 |
| 2 | Ovarian cancer: strategies for overcoming resistance to chemotherapy Hit paper breakdown → | 2003 | 965 |
| 3 | Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2006 | 794 |
| 4 | Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval Hit paper breakdown → | 2010 | 753 |
| 5 | Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types Hit paper breakdown → | 2002 | 683 |
| 6 | Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven Hit paper breakdown → | 2008 | 667 |
| 7 | Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Hit paper breakdown → | 1999 | 574 |
| 8 | Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Hit paper breakdown → | 1989 | 534 |
| 9 | A decade of clinical development of PARP inhibitors in perspective Hit paper breakdown → | 2019 | 512 |
| 10 | 2006 | 485 | |
| 11 | Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer Hit paper breakdown → | 2009 | 449 |
| 12 | Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research Hit paper breakdown → | 2013 | 423 |
| 13 | 2009 | 404 | |
| 14 | 2011 | 380 | |
| 15 | 2017 | 320 | |
| 16 | 2012 | 272 | |
| 17 | 2006 | 221 | |
| 18 | 1997 | 221 | |
| 19 | 2011 | 210 | |
| 20 | 2016 | 206 |
About Stan B. Kaye
Stan B. Kaye is a scholar working on Oncology, Reproductive Medicine, Molecular Biology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 217 papers that have together received 19.3k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (71 papers), Cancer Treatment and Pharmacology (30 papers), PARP inhibition in cancer therapy (26 papers), Cancer Genomics and Diagnostics (16 papers), Colorectal Cancer Treatments and Studies (14 papers), Endometrial and Cervical Cancer Treatments (14 papers), Renal cell carcinoma treatment (12 papers) and Cancer Mechanisms and Therapy (11 papers). The work is most often cited by research in Reproductive Medicine (2.7k citations), Oncology (8.0k citations), Cancer Research (2.8k citations), Pulmonary and Respiratory Medicine (3.4k citations) and Molecular Biology (7.4k citations). Stan B. Kaye has collaborated with scholars based in United Kingdom, United States and Netherlands. Frequent co-authors include Johann S. de Bono, Roshan Agarwal, Timothy A. Yap, Alan Ashworth, Andrew Tutt, James Carmichael, David S.P. Tan, Jan H.M. Schellens, Peter C.C. Fong and Helen Swaisland. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Cancer, European Journal of Cancer, Annals of Oncology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.